A post-hoc analysis of data from two clinical trials showed that nano-encapsulated sirolimus with pegylated-adricase (NASP) may be effective for promoting tophus resolution and lowering serum uric acid in patients with uncontrolled gout.
Promising Combination Treatment for Gout
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.